Snake bites by European vipers in Mainland France in 2017–2018: comparison of two antivenoms Viperfav® and Viperatab®
- 5 March 2020
- journal article
- research article
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 58 (11) , 1050-1057
Abstract
Context: Today, immunotherapy with Fab or F(ab′)2 fragments is considered as a gold standard treatment for patients bitten by vipers. We compared the efficiency of two antivenoms, Viperfav® and Viperatab®, in mainland France in 2017–2018 with data provided by the French poison control centre (PCC). Methods: Patients with a moderate (2a and 2b) or severe (3) envenomation after a European viper bite and treated with immunotherapy were included and the markers chosen were the risk of post-antivenom treatment worsening, duration of hospital stay and persistent functional discomfort on day 15. Statistical studies were based on multivariate data analysis. Results: Two hundred and ninety-seven cases were recorded. One hundred and eighty-two (61.3%) patients received Viperfav® and 115 (38.7%) received Viperatab®. Compared to Viperfav®, use of Viperatab® significantly increased the risk of post-antivenom treatment worsening (OR* 12.05; 95%CI [3.11; 46.70]; p < .001). No significant difference between these antivenoms was recorded with respect to the duration of hospital stay and persistent functional discomfort on day 15. Viperfav® and Viperatab® have a similar tolerance (p > .21). Otherwise, duration of hospitalisation was significantly increased by a delay of immunotherapy infusion of more than 12 h (OR 2.70; 95%CI [1.45–5.06]; p = .002) or a preventive administration of LMWH (OR 6.55; 95%CI [1.58–27.13]; p=.02). Discussion: While Viperfav® and Viperatab® have a similar tolerance, our data show that Viperatab® was associated with a higher risk of post-antivenom treatment worsening compared to Viperfav®. Furthermore, this study confirms that the antivenom should be used as soon as possible. Indeed, patients receiving the immunotherapy infusion from the grade 2b presented significantly more frequent exacerbated symptoms (OR 3.99; 95%CI [1.16–13.73]; p=.028) after the antivenom infusion compared to grade 2a group. Conclusions: Whereas no significant difference between these antivenoms was recorded with respect to the duration of hospital stay and persistent functional discomfort on day 15, use of Viperatab®, compared to Viperfav®, significantly increased the risk of post-antivenom treatment worsening (OR* 12.05; 95%CI [3.11; 46.70]; p < .001). Taken together, these data show that Viperfav® is the treatment of choice for the management of snake bites in France.Keywords
This publication has 23 references indexed in Scilit:
- Asp Viper (Vipera aspis) Envenomation: Experience of the Marseille Poison Centre from 1996 to 2008Toxins, 2009
- Reappraisal of Vipera aspis Venom NeurotoxicityPLOS ONE, 2007
- A Nationwide Study ofVipera BerusBites During One Year—Epidemiology and Morbidity of 231 CasesClinical Toxicology, 2006
- Pharmacokinetic-Pharmacodynamic Relationships of Immunoglobulin Therapy for EnvenomationClinical Pharmacokinetics, 2003
- Toxicity evolution of Vipera aspis aspis venom: identification and molecular modeling of a novel phospholipase A2 heterodimer neurotoxin1FEBS Letters, 2002
- First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenomingJournal of Internal Medicine, 1997
- Antivenom treatment in Vipera berus envenoming—report of 30 casesJournal of Internal Medicine, 1994
- An affinity purified ovine antivenom for the treatment of Vipera berus envenomingToxicon, 1992
- Prediction Error and Its Estimation for Subset-Selected ModelsTechnometrics, 1991
- The Impact of Model Selection on Inference in Linear RegressionThe American Statistician, 1990